Can your genes predict the best eye injection for AMD?

NCT ID NCT06952452

Recruiting now Knowledge-focused Sponsor: Parc de Salut Mar Source: ClinicalTrials.gov ↗

First seen Nov 20, 2025 · Last updated May 23, 2026 · Updated 16 times

Summary

This study looks at how a person's genes influence their response to two common eye injection treatments for wet age-related macular degeneration (AMD). About 630 adults aged 50 and older with untreated wet AMD will receive either ranibizumab or bevacizumab and be followed for 3 years. The goal is to see if certain genetic markers can help predict which treatment works best for each patient.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Hospital Universitario de Canarias
RECRUITING

San Cristóbal de La Laguna, Santa Cruz De Tenerife, Spain

Contact

Contact Email: •••••@•••••
Hospital de la Santa Creu i Sant Pau
RECRUITING

Barcelona, Spain

Contact

Contact Email: •••••@•••••
Hospital la Esperanza
RECRUITING

Barcelona, Spain

Contact

Contact Email: •••••@•••••
Unidad Central de Investigación Clínica y Ensayos Clínicos (UCICEC La Paz)
RECRUITING

Madrid, 28046, Spain

Contact

Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

WET AGE RELATED MACULAR DEGENERATION